Methods and compositions for treating allergic asthma using desc

Details Methods and compositions for treating allergic asthma using desc Methods and compositions for treating allergic asthma using desc

1998-07-06

1999-10-05

Jordan, Kimberly

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514826, 514864, A61K 3144

Patent

active

059624647

ABSTRACT:
Methods utilizing descarboethoxyloratadine ("DCL"), for the treatment of allergic disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. Also included are methods for the treatment of allergic asthma using DCL and either a decongestant or a leukotriene inhibitor, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. The invention also encompasses the administration of DCL in a nasal or oral spray.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon
patent: 4282233 (1981-08-01), Villani
patent: 4659716 (1987-04-01), Villani et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5595997 (1997-01-01), Aberg et al.
Babe et al., 1996, "Histamine, Bradykinin, and Their Antagonists", Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed., pp. 581-593 and 598-599.
McCue, J., 1996, "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients", Arch. Fam. Med. 5:464-468.
Andersen et al., 1995, "Adverse Drug Interactions Clinically Important for the Dermatologists", Arch. Dermatol. 131:468-473.
Peggs et al., 1995, "Antihistamines: The Old and New", American Family Physician 52(2):593-600.
Berthon et al., 1994, "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophillic Leukemia Cells (RBL-2H3)", Biochemical Pharmacology 47(5):789-794.
Brandes et al., 1994, "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H.sub.1 -Antihistamines: Predictive In Vitro Correlates", J. Nat. Can. Inst. Reports 86(10): 770-775.
Kleine-Tebbe et al., 1994, "Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H.sub.1 -antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol. 93(2):494-500.
Miadonna et al., 1994, "Inhibitory Effect of the H.sub.1 Antagonist Loratadine on Histamine Release from Human Basophils", Int. Arch. Allergy Immunol. 105:12-17.
Simons, F.E.R., 1994, "H.sub.1 -Receptor Antagonists Comparative Tolerability and Safety", Drug Safety 10(5):350-380.
Zhong et al., 1994, "HPLC-Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma", Pharmazie 49(10):736-739 (English abstract attached).
Quercia et al., 1993, "Focus on loratadine: A new second-generation nonsedating H.sub.1 -receptor antagonist", Hosp. Formul. 28:137-149, 153.
Lavrijsen et al., 1993, "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes", Abstract 1233 Eur. J. Allergy Clin. Immunol. 48(Suppl. 16):34.
Roman et al., 1993, "Loratadine A Review of Recent Findings in Pharmacology, Pharmacokinetics, Efficacy, and Safety, with a Look at Its Use in Combination with Pseudoephedrine", Clinical Reviews in Allergy 11:89-110.
Van Peer et al., 1993, "Ketoconazole Inhibits Loratadine Metabolism in Man", Abstract 1234 Eur. J. Allergy Clin. Immunol. 48(Suppl. 16):34.
Product Insert CR-318/17597400 7/93 Schering Corporation (1992, 1993).
Brandes et al., 1992, "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", Cancer Research 52:3796-3800.
Kaliner, M., 1992, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician 45(3):1337-1342.
Knowles, 1992, "Astemizole and Terfenadine -- Induced Cardiovascular Effects ", Canadian J. Hosp. Pharm. 45(1):33, 37.
Parkinson et al., 1992, "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 in Rats and Mice", Biochemical Pharmacology 43(10):2169-2180.
Van Cauwenberge, P., 1992, "New Data on the Safety of Loratadine", Drug Invest. 4(4):283-291.
Barnett et al., 1991, "Pharmacology of Non-Sedating H.sub.1 Antihistamines", New Perspective in Histamine Research pp. 181-196.
"Antihistamines", 1990, Chapter 16 Side Effects of Drugs Annual 14:135-138 Elsevier Science Publishers.
Gengo, F.M, 1990, "Delimma: Antihistamine Selection: Use vs. Side Effects", U.S. Pharmacist pp. 59-72, 92.
Clissold et al., 1989, "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy", Drugs 37:42-57.
"Antihistamines", 1988, Chapter 16 Side Effects of Drugs Annual 12:142-143 Elsevier Science Publishers.
Simons et al., 1988, "Astemizole -- Induced Torsades de Pointes", Lancet p. 624.
Temple et al., 1988, "Loratadine, an Antihistamine, Blocks antigen-and lonophore -Induced Leukotriene Release From Human Lung In Vitro", Prostaglandins 35(4):549-554.
Hilbert et al., 1987, "Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. 27:694-698.
Craft, 1986, "Torasde de Pointes After Astemizole Overdose", British Med. J. 292:660.
Barnett et al., 1984, "Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine", Agents and Actions 14(5/6):590-597.
Wood, 1979, "Antimotion Sickness and Antiemetic Drugs", Drugs 17(17):471-479.
Cohen et al., 1972, "Meclizine and Placebo in Treating Vertigo of Vestibular Origion", Arch. Neurol. 27:129-135.
Goodman and Gilman's, 1996, The Pharmacological Basis of Therapeutics, 9th Ed. p. 148, 588-592.
Carmeliet, 1992, "Voltage-and Time-Dependent Block of the Delayed K.sup.+ Current in Cardiac Myocytes by Dofetilide", J. Pharmacol. Exper. Ther. 262:809-817.
Lunde, I., 1990, "Antihistamines", Side Effects of Drugs 14:135-138.
Dukes, M.N.G. et al., 1988, "Side Effects of Drugs Annual 12", Elsevier Science Publishers B.V. pp. 142-143.
Ebert, W., 1977, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", Pharamaceutical Technology 1:44-50.
Berge, S. et al., 1977, "Pharmaceutical Salts", J. of Pharm. Sci. 66:1-19.
Cheung, B.S.K. et al., 1992, "Investigation of Anti-Motion Sickness Drugs in the Squirrel Monkey", J. Clin. Pharmacol. 32:163-175.
Dorje, F. et al., 1991, "Antagonist Binding Profiles of Five CLoned Human Muscarinic Receptor Subtypes", J. Pharmacol. and Exper. Therap. 256:727-733.
Herzog, A.R. et al., 1989, "Urinary Incontinence: Medical and Psycosocial Aspects", Annu. Rev. Gerontol. Geriatrics 9:74-119.
Kohl and MacDonald, 1991, "New Pharmacologic Approaches to the Prevention of Space/Motion Sickness", J. Clin. Pharmacol. 31:934-946.
Kubo, N. et al., 1987, "Antimuscarinic Effects of Antihistamines: Quantitative Evaluation by Receptor-Binding Assay", Japan J. Pharmacol. 43:277-282.
Lathers, C. et al., 1989, "Pharmacology in Space", Tips 10:243-250.
Levin and Wein, 1982, "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder", J. Urology 128:396-398.
Massad, C. et al., 1992, "The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride", J. Urology 148:595-597.
Mirakhur and Dundee, 1983, "Glycopyrrolate: Pharmacology and Clinical Use", Anaesthesia 38:1195-1204.
Mitchelson, F., 1992, "Pharmacological Agents Affecting Emesis", Drugs 43:443-463.
Muskat, Y. et al., 1996, "The Use of Scopolamine in the Treatment of Detrusor Instability", J. Urology 156:1989-1990.
Nelemans, F.A., 1988, "Antiallergic and Antitussive Drugs", Side Effects of Drugs 12:144-147.
Resnick, N. 1995, "Urinary Incontinence", The Lancet 346:94-99.
Wein, A., 1995, "Pharmacology of Incontinence", Urol. Clin. N. Am. 22:557-577.
Yarker, Y. et al., 1995, "Oxybutynin", Drugs & Aging 6:243-262.
Petrin, A. et al., 1974, "Motion sickness and its Treatment", Schweiz. Rundechau Med. PRAXIS 63:79-81 (With English Abstract).
Wood, C.D. et al., 1987, "Mechanisms of Antimotion Sickness Drugs", Aviation, Space, and Environmental Med. 58(9):A262-A265.

Affiliated with

Also associated with

Rating

Methods and compositions for treating allergic asthma using desc does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating allergic asthma using desc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating allergic asthma using desc will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1171748